Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

2006 • 1,745 citations

2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

2006 • 1,657 citations

One-Sample Multiple Testing Procedure for Phase II Clinical Trials

1982 • 987 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Non-Small Cell Lung Cancer

2016 • 873 citations

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

2006 • 603 citations

Small-cell lung cancer

2005 • 494 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

2007 • 356 citations

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

2001 • 236 citations

Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402

2008 • 236 citations

Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301

2006 • 227 citations

Lung cancer: principles and practice

2001 • 175 citations

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.

1996 • 132 citations

Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.

1988 • 131 citations

A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II‐DNA Complex

1998 • 107 citations

Cytotoxicity of Amrubicin, a Novel 9‐Aminoanthracycline, and Its Active Metabolite Amrubicinol on Human Tumor Cells

1998 • 100 citations

Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer

2009 • 85 citations

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs

1998 • 72 citations

Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas

2005 • 72 citations

Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC)

2006 • 40 citations

Vascular Endothelial Growth Factor Level as a Prognostic Determinant of Small Cell Lung Cancer in Japanese Patients

2005 • 33 citations

Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative

1989 • 24 citations

Amrubicin for the Treatment of Small Cell Lung Cancer: Does Effectiveness Cross the Pacific?

2007 • 22 citations

Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer

2008 • 20 citations

Cited By (0)

Loading...